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The Journal of Immunology
IL-9 Expression by Invariant NKT Cells Is Not Imprinted
during Thymic Development
Marta Monteiro,*,† Ana Agua-Doce,*,† Catarina F. Almeida,*,† Diogo Fonseca-Pereira,*
Henrique Veiga-Fernandes,* and Luis Graca*,†
Invariant NKT (iNKT) cell thymic development can lead to distinct committed effector lineages, namely NKT1, NKT2, and NKT17.
However, following identification of IL-9–producing iNKT cells involved in mucosal inflammation, their development remains
unaddressed. In this study, we report that although thymic iNKT cells from naive mice do not express IL-9, iNKT cell activation in
the presence of TGF-b and IL-4 induces IL-9 secretion in murine and human iNKT cells. Acquisition of IL-9 production was
observed in different iNKT subsets defined by CD4, NK1.1, and neuropilin-1, indicating that distinct functional subpopulations
are receptive to IL-9 polarization. Transcription factor expression kinetics suggest that regulatory mechanisms of IL-9 expression
are shared by iNKT and CD4 T cells, with Irf4 and Batf deficiency deeply affecting IL-9 production. Importantly, adoptive
transfer of an enriched IL-9+ iNKT cell population leads to exacerbated allergic inflammation in the airways upon intranasal
immunization with house dust mite, confirming the ability of IL-9–producing iNKT cells to mediate proinflammatory effects
in vivo, as previously reported. Taken together, our data show that peripheral iNKT cells retain the capacity of shaping their
function in response to environmental cues, namely TGF-b and IL-4, adopting an IL-9–producing NKT cell phenotype able to
mediate proinflammatory effects in vivo, namely granulocyte and mast cell recruitment to the lungs. The Journal of Immunol-
ogy, 2015, 195: 3463–3471.
N
atural killer T cells comprise a minor subset of T lym-
phocytes reactive to lipid Ags presented by CD1d on the
surface ofAPCs andother cell types (1, 2).Ag specificity
is determined by the TCR repertoire, which allows the subdivision
ofNKTcells into two categories: type I and type II. Type INKTcells
express a semi-invariant TCR formed by a restricted number of
TCR b-chains associated with an invariant a-chain (Va14-Ja18
inmice, Va24-Ja18 in humans). For this reason, type I NKT cells
are frequently named invariant NKT (iNKT) cells. They specif-
ically recognize a-galactosylceramide (a-GalCer), a glycolipid
that has been widely used for their reliable identification and
stimulation. Type II NKT cells have a broader TCR repertoire, en-
abling the recognition of other lipid Ags, and they are unable to
bind a-GalCer (3–5).
Despite being aminor population of lymphocytes, NKT cells are
important early orchestrators of immune responses due to their
remarkable capacity of secreting high levels of cytokines rapidly
after their activation, including IFN-g, IL-4, and IL-17 (6–8). Such
fast production of cytokines contributes to the initial regulation of
several inflammatory responses, such as the ones associated with
allergic and autoimmune diseases, antitumor and mucosal-protective
responses, and infection (9–13).
During thymic development,NKTcells receive signals inducing
the expression of lineage-specific transcription factors, which
determine their competence to become IFN-g, IL-4, or IL-17
secretors (6–8) (referred to as NKT1, NKT2, and NKT17, re-
spectively; reviewed in Ref. 14). Hence, NKT1 cells express T-bet,
NKT2 cells expressGATA-3, andNKT17-committed cells express
retinoic acid–related orphan receptor gt (15).
NKT cells expressing non-classical functions have also been
documented, including Foxp3+ regulatory NKT cells (16, 17),
follicular helper NKT cells (18–21), and NKT cells secreting
further types of cytokines, such as IL-10 (22) and IL-9 (8, 23–25).
Being the archetype cytokine of Th9 responses, IL-9 secretion by
invariant (iNKT) cells has been investigated (25). Not only were
IL-9–producing iNKT cells identified in vivo, but also these cells
were reported to confer protection against DSS-induced colitis
(25). However, the development of IL-9–secreting iNKT cells has
never been addressed.
The ability of peripheral NKT cells to specialize in distinct
functional subsets has been controversial (26, 27). However, it is
clear that, in addition to thymic generation of NKT1, NKT2, and
NKT17 subsets, some iNKT cells can leave the thymus uncom-
mitted to a particular functional phenotype, namely NKT17, and
adopt that phenotype when exposed to adequate inflammatory
mediators (14, 28, 29). We now establish that IL-9–producing
NKT cells (NKT9) do not acquire this function in the thymus, but
are readily generated in mice and humans upon activation in pres-
ence of TGF-b and IL-4. Distinct functional iNKT cell subsets
could become IL-9 secretors, indicating a shared responsiveness
to signals instructing the acquisition of NKT9 fate. Furthermore,
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IL-9 production by iNKT cells aggravated allergic inflammation in
mice exposed to intranasal house dust mite (HDM). Collectively,
our data show that IL-9 expression is imprinted in iNKT cells only
after peripheral activation under adequate inflammatory signals
(IL-4 andTGF-b) and likely contributes to the initial Th9 response.
Materials and Methods
Mice
C57BL/6J (H-2b), BALB/c (H-2d), B6.129S-Batftm1.1Kmm/J (H-2b, Batf2/2),
B6.129S1-Irf4tm1Rdf/J (H-2b, Irf4fl), and B6.Cg-Tg(Vav1-cre)A2Kio/J (H-2b,
Vav-iCre)mice obtained fromThe JacksonLaboratory (BarHarbor,ME) and
Foxp3gfp knock-in mice (H-2b) obtained from University of Washington
(Seattle, WA) were bred and maintained under specified pathogen-free
conditions at the Instituto Gulbenkian de Ciência and Instituto de Medic-
ina Molecular. For each experiment animals were sex and age matched. All
animal work complied with the European Directive 63/2010/EU, the
guidelines of the Federation for the European Laboratory Animal Science
Associations, and regulations of Institutional Ethical Comities.
Isolation of human peripheral blood cells
Heparinized venous blood samples were obtained from healthy volunteers
of both sexes after informed consent. The procedures were reviewed and
approved by the Ethical Board of the Faculty of Medicine, University of
Lisbon, Portugal. PBMCs were isolated by centrifugation on a Histopaque-
1077 Hybri-Max density gradient (Sigma-Aldrich) and T cells were enriched
as described elsewhere (16).
Flow cytometry and cell sorting
MouseCD1d tetramers coupled toPEand loadedwithPBS57 (an iNKTcell
ligand analog to a-GalCer) were supplied by the National Institutes of
Health Tetramer Facility. Fluorochrome-labeled mAbs specific to mouse
TCRb (H57-597), NK1.1 (PK136), CD4 (RM4-5), CD3 (145-2C11),
CCR3 (83103), Gr-1 (RB68C5),MHC class II (M5/114.15.2), c-Kit (2B8),
CD19 (eBio1D3 or MB19-1), CD24 (M1/69), CD44 (IM7), IL-4 (11B11),
IL-9 (RM9A4), IFN-g (XMG1.2), and streptavidin were purchased from
eBioscience, BD Biosciences, or BioLegend. IL-9 polyclonal Ab conju-
gated with fluorescein was provided by J. Van Snick (Ludwig Institute for
Cancer Research, Brussels Branch, Cellular Genetics Unit and Experi-
mental Medicine Unit, Christian de Duve Institute of Cellular Pathology,
Université de Louvain). For intracellular cytokine detection, cells were
incubated for 2 h with 50 ng/ml PMA, 500 ng/ml ionomycin, 10 mg/ml
brefeldin A (Sigma-Aldrich), and BD GolgiStop (BD Biosciences). After
Ab surface staining, cells were fixed and permeabilized using BD Cytofix/
Cytoperm Plus (BD Biosciences) and then incubated with unconjugated
anti-CD16/32 (clone 2.4G2) rat Ab and with anti-cytokine Abs. Data were
collected in a BD LSRFortessa (BD Biosciences) and analyzed using
FlowJo (Tree Star). For cell sorting, murine iNKT cells were first enriched
by magnetic separation, as described elsewhere (16), and samples were
sorted on FACSAria I (BD Biosciences).
Cell culture
FACS-sortedpopulationsofmouse iNKTorCD4Tcellswerecultured in96-
well round-bottom plates previously coated with anti-CD3 (clone 145-
2C11, eBioscience) at 3 mg/ml. Culture medium was RPMI 1640 with
GlutaMAX, supplemented with 10% FBS, 1% HEPES, 1% penicillin/
streptomycin, 1% sodium pyruvate, 0.1% 2-ME, and 0.05% gentamicin (all
from Life Technologies). For Th9 differentiation, cultures were supple-
mentedwithTGF-b (5 ng/ml, R&DSystems), IL-2 (5 ng/ml, eBioscience),
IL-4 (20 ng/ml, eBioscience), and anti-CD28 (2 mg/ml, eBioscience). In
some conditions, in-house–produced anti–IL-4 (11B11) or anti–TGF-b
(1D11) was added to the culture. Human cells were cultured in 96-well
flat-bottom plates previously coated with anti-CD3 (clone OKT3, BD Bio-
sciences) at 1 mg/ml. Culture medium was RPMI 1640 with GlutaMAX,
supplemented with 10% FBS, 1% HEPES, 1% penicillin/streptomycin,
and 0.05% gentamicin (all from Life Technologies). Th9 differentiation
of human cells was induced by adding TGF-b (5 ng/ml, R&D Systems),
IL-4 (25 ng/ml, eBioscience), IL-2 (50 U/ml, eBioscience), anti–IL-12/
23, and anti–IFN-g (10 mg/ml, eBioscience) and anti-CD28 (1 mg/ml,
eBioscience).
Cytokine detection assays
Measurement of IL-9 in culture supernatants was performed using the
mouse IL-9 Flex Set (BD Biosciences). IL-4 was detected in MaxiSorp
plates (Nunc) using a murine IL-4 ELISA kit (PeproTech). All assays were
performed according to the manufacturers’ instructions.
Adoptive cell transfer and allergic airways disease induction
Wild-type C57BL/6J mice were anesthetized, the trachea was surgically
exposed, and 13 104 iNKT cells were injected. Mice were challenged i.n.
with 25ml PBS containing 25mg crude extract ofHDM(Greer, Lenoir, NC)
plus 500 ng thymic stromal lymphopoietin (TSLP; PeproTech) daily for 5 d
and sacrificed 24 h after the last challenge. Some mice received i.v. 1 mg
anti–IL-9 mAb (clone 9C1, Bio X Cell) 1 d before and after iNKT cell
transfer. To assess airway infiltration, the trachea was cannulated, the air-
ways were lavaged three times with 1 ml PBS, and the bronchoalveolar
lavage (BAL) was collected. Cell populations were assessed by flow
cytometry. Lungs were perfused with 4% formalin solution (Sigma-
Aldrich) and fixed at 4˚C. Tissue samples were embedded in paraffin,
sectioned, and stained with H&E. Images were taken using a Leica
DM2500 microscope and a Leica DFC420 camera.
RNA extraction and RT-PCR
RNAwas extracted from 1,000 to 50,000 FACS-sorted cells with an RNeasy
Microkit (Qiagen) followingthemanufacturer’s instructions,withcellsbeing
directly sorted into RLT buffer. cDNA synthesis was performed using ran-
dom primers and SuperScript III reverse transcriptase (Life Technologies).
Transcripts were detected with the following primers: Eif1a, forward, 59-
ACACGTAGATTCCGGCAAGT-39, reverse, 59-AGGAGCCCTTTCCCA-
TCTC-39; Il9, forward, 59-GACCAGCTGCTTGTGTCTCT-39, reverse,
59-AAGGACGGACACGTGATGTT-39; Gata3, forward, 59-CACTACCTT-
TGCAATGCCTG-39, reverse, 59-AGCTTGTAGTACAGCCCACA-39; Spi1
(PU.1), forward, 59-CCAACGTCCAATGCATGACT-39, reverse, 59-GCA-
TGTAGGAAACCTGGTGA-39; Batf, forward, 59-TTAGAACCATGCCT-
CACAGC-39, reverse, 59-AGCTGCGTTCTGTTTCTCCA-39; Irf4, forward,
59-AGCCAGCTGGATATCTCTGA-39, reverse, 59-ATAATCCCTCCAGCT-
CCTGT-39. Real-time PCRs were performed using Power SYBR Green
PCRmaster mix and the RT-PCRViiA 7 sequence detection system (Life
Technologies).
Statistical analysis
Data were analyzed using GraphPad Prism 5. The p values were calculated
by a nonparametric unpaired Mann–Whitney U test, and p values , 0.05
were deemed significant.
Results
Expression of IL-9 mRNA and protein are undetectable in
thymic iNKT cells
Although IL-9–producing iNKT cells were identified in the gut (25),
a putative thymic commitment of these cells was not addressed. To
investigate whether the genetic program leading to IL-9 expression
in iNKT cells is initiated during development, we isolated thymic
iNKT cells from naive C57BL/6J mice and assessed intracellular
expression of cytokines ex vivo. As shown in Fig. 1A, ∼30% of
iNKT cells expressed IL-4, 5% expressed IFN-g, and 5% coex-
pressed both cytokines. IL-9 expression, however,was undetectable.
To increase the detection limit, we assessed by real-time RT-
PCR the presence of Il9 transcripts in thymic iNKT cells sorted
either in bulk or subdivided according to their developmental stage
defined by CD24 and CD44 coexpression: CD24hiCD44lo (stage 0),
CD24loCD44lo (stage 1), and CD24loCD44hi (stage 2). The later
subset was analyzed both unfractionated and subdivided according
to CD4 and NK1.1 expression (Fig. 1B). In contrast with the pre-
dictable expression of Il4, Gata3, Ifng, and Tbx21, which were
present in total iNKT cells and in the most mature subsets, expres-
sion of Il9, similar to Foxp3, was undetectable in all thymic iNKT
subpopulations (Fig. 1C and data not shown).
These data indicate that IL-9 expression in iNKT cells is induced
outside the thymus.
iNKT cells can be polarized toward IL-9 production
Although undetectable in naive mice, Foxp3+ iNKT cells can be
identified in vivo after immunization in several models, includ-
ing 1) in cervical lymph nodes in experimental autoimmune















encephalomyelitis, 2) in mesenteric lymph nodes following glyco-
lipid ingestion, and 3) in the lungs during acute and chronic allergic
airways disease (M. Monteiro and L. Graca, unpublished results
and Refs. 14, 16). TGF-b is critical for upregulation of Foxp3 in
iNKT cells and also for Th9 differentiation of conventional naive
CD4 T cells. We have therefore investigated the impact of TGF-b
on IL-9 expression by iNKT cells activated in vitro (Fig. 2,
Supplemental Fig. 1). Purified splenic iNKT cells stimulated in the
presence of IL-2 alone did not show significant expression of IL-9,
but exogenous addition of TGF-b promoted massive IL-9 intracellular
FIGURE1. IL-9 expression by iNKT cells is undetectable in the thymus. Thymic iNKT cells were isolated from naive C57BL/6J mice, and expression of
cytokines and transcription factorswas assessed by intracytoplasmic staining and quantitativeRT-PCR. (A) Intracytoplasmic cytokine expression by thymic
iNKT cells following stimulation with PMA/ionomycin in presence of protein transport inhibitors. Isotype control for IL-4 and IFN-g stainings is shown in
the left panel. IL-9was stained using a polyclonalAb. (B) Identification of iNKTcell thymic developmental stages based onCD24andCD44expression after
gating of CD1d/PBS57 tetramer+ cells. CD24loCD44hi iNKT cells were further subdivided according to expression of CD4 and NK1.1. (C) Relative ex-
pression of Il9,Foxp3, Il4,Gata3, Ifng, and Tbx21 transcripts in unfractionated thymic iNKT cells and in iNKT cells from the distinct thymic developmental
stages as defined in (B). Samples were sorted by FACS and analyzed in triplicate. Expression levels are relative to eukaryotic translation initiation factor 1A
(Eif1A) mRNA. Error bars represent SE. Data are representative of three experiments performed independently. N.D., not detected.
FIGURE 2. IL-9 production is induced in iNKT cells following stimulation in presence of TGF-b and IL-4. Splenic iNKTand CD252 CD4 T cells from
C57BL/6 mice were purified by FACS and stimulated in vitro in the presence or absence of TGF-b and IL-4, as well as IL-4 (11B11) or TGF-b (1D11)
blocking Abs, as indicated. Culture media in all conditions were supplemented with IL-2, and supernatants were harvested after 72 h of culture. (A) In-
tracellular expression of IL-9 and Foxp3 in iNKT cells cultured in the absence (left) or presence (right) of TGF-b, using an anti–IL-9 polyclonal Ab. (B) IL-9
concentration in supernatants of iNKT (left) and CD4 T cell (right) cultures supplemented with the indicated cytokines. (C) Intracellular expression of IL-9
and Foxp3 in iNKT cells stimulated under the indicated conditions, using a commercial anti–IL-9 mAb (RM9A4). (D) Concentration of IL-4 in the su-
pernatant of iNKT cell cultures. (E) IL-9 concentration in iNKT cell culture supernatants upon stimulation in the presence or absence of TGF-b and various
concentrations of neutralizing anti–IL-4 Ab (11B11). (F) IL-9 concentration in iNKT (left) and CD4 T cell (right) culture supernatants upon stimulation in
the presence of the indicated cytokines and neutralizingAbs. (G) Intracellular expression of IL-9 in humanCD1d/PBS57+ iNKT cells after 5 d of stimulation
in the presence or absence of the IL-9–inducing cytokine mixture, as indicated. Bars graphs represent the average of triplicate or quadruplicate cell cultures
per assay and error bars indicate SE. Data are representative of three experiments performed independently. *p , 0.05. N.D., not detected.















expression and secretion (Fig. 2A–C). Notably, iNKT cells isolated
from thymus and liver also responded to stimulation in presence of
TGF-b with significant upregulation of Il9 mRNA and potent IL-9
secretion (Supplemental Fig. 1).
In contrast to CD4T cells, which required exogenous addition of
IL-4 toundergoTh9polarization, asdescribed (30, 31) (Fig. 2B, 2F,
Supplemental Fig. 1), stimulation of iNKT cells in the presence of
TGF-b alone was sufficient to induce high IL-9 secretion, and
exogenous IL-4 addition did not increase IL-9 levels in super-
natants (Fig. 2B). However, unlike CD4 T lymphocytes,
iNKT cells produce significant amounts of IL-4 upon activation
(Fig. 2D). To understand whether endogenous IL-4 had an impact
on IL-9 induction in iNKT cells, we added to the cultures a IL-4–
blocking mAb (11B11; Fig. 2E, 2F). In these conditions, IL-9 se-
cretion by iNKT cells decreased inversely to the concentration of
anti–IL-4, confirming that IL-4 is critical for the induction of
a Th9-like program in iNKT cells (Fig. 2E). Low levels of secreted
IL-9 could also be detected in cultures set without exogenous TGF-
b, suggesting that the medium could contain traces of TGF-b.
Indeed, addition of neutralizing anti–TGF-b mAb (1D11) com-
pletely abrogated IL-9 secretion by iNKT cells (Fig. 2F). Finally,
we observed that human iNKT cells also induce IL-9 production
when activated under NKT9-promoting conditions (Fig. 2G).
These observations show that both mouse and human
iNKT cells are able to respond to the same stimuli promoting Th9
polarization in conventional CD4 T cells, thus supporting that
developmentally mature iNKT cells retain the capacity of initi-
ating a Th9-like program in response to the inflammatory context
of their activation.
Expression of IL-9 can be induced in different iNKT cell
subpopulations
Subdivision of iNKT cells into distinct subsets according to CD4
and NK1.1 expression has been claimed to relate to predominant
cell functions (8, 15, 32). In particular, IL-4 secretion has been as-
sociated with CD4+ iNKT cells, whereas an IFN-g–secreting phe-
notype has been attributed to NK1.1+ iNKT cells, and IL-17
secretion to the CD42NK1.12 subset. We have therefore investi-
gated whether different iNKT cell subsets defined by the expression
of CD4 and NK1.1 have any restriction in their capacity of acquiring
IL-9 expression (Fig. 3). The four corresponding iNKT subpopula-
tions (NK1.12CD4+, NK1.1+CD4+, NK1.1+CD42, and NK1.1–CD4–)
were sorted and IL-9 expression was assessed following 72 h of
stimulation under NKT9-polarizing conditions (Fig. 3A–C). Both
IL-9 and Foxp3 were detectable in all iNKT cell subsets stimulated
in the presence of TGF-b, with NK1.1+CD4+ and NK1.1+CD42
subpopulations presenting the highest frequency of IL-9–express-
ing cells and amount of IL-9 secretion (Fig. 3B, 3C).
We have also assessed the capacity of IL-9 induction in iNKT
cells subdivided according to neuropilin-1 (Nrp-1) expression, a re-
ceptor expressed by recent thymic emigant iNKT cells that are
enriched in NKT17 committed cells (Fig. 3D). After 72 h of
stimulation in presence of TGF-b, significant amounts of IL-9
were detected in culture supernatants of both Nrp-1– and Nrp-1+
iNKT cells (Fig. 3E).
Collectively, these results show that an NKT9 functional pro-
gram can be induced in all iNKT cell subsets commonly associ-
ated with IL-4, IFN-g, or IL-17 secretion.
Transcriptional control of Il9 in iNKT cells
Transcriptional regulation of Th9 differentiation in conventional
CD4 T cells is complex, as it relies on several transcription factors,
including PU.1,GATA-3, BATF, and IFN regulatory factor (IRF)-4
(31, 33–35). To identify the controlling factors of IL-9 gene ex-
pression in iNKT cells, we first defined the kinetics of IL-9 ex-
pression at protein and mRNA levels to determine the best time
point for analysis. For that purpose, we purified and stimulated
in vitro splenic iNKT cells in the presence of TGF-b and analyzed
FIGURE 3. Expression of IL-9 can be induced in iNKT cell subpopulations defined by expression of NK1.1 and CD4 or Nrp-1. (A–C) Splenic iNKT cells
from nonmanipulated C57BL/6micewere sorted into four populations, according to expression of CD4 and NK1.1, and stimulated in vitro in the presence of
IL-2 and TGF-b. (A) FACS plots showing the gating strategy for cell sorting. (B) Intracellular Foxp3 or IL-9 expression evaluated after 3 d of culture. (C)
Frequency of IL-9+ cells (left) and IL-9 concentration in culture supernatants (right). Results are representative of three independent experiments. (D and E)
Nrp-1+ andNrp-12 iNKTcellswere purified byFACSand stimulated invitro in the presence of IL-2with orwithout TGF-b. (D) FACSplots showing thegating
strategy for cell sorting. (E) Concentration of IL-9 in culture supernatants of Nrp-1+ and Nrp-12 iNKT cells after 3 d of stimulation. Bar graphs represent the
average of triplicate cell cultures per assay (with the exception of NK1.12CD42 cultures, which had no replicates within each experiment) and error bars
indicate SE. Data are representative of two (D) or three (A–C) experiments performed independently. CD4-SP, NK1.12CD4+ (CD4 single positive); DN,
NK1.12CD42 (double-negative); DP, NK1.1+CD4+ (double-positive); NK1.1-SP, NK1.1+CD42 (NK1.1 single positive). *p, 0.05. N.A., not assessed.















Il9 expression and IL-9 concentration in the supernatant after 12,
36, 60, and 84 h. Whereas IL-9 concentration in supernatants
progressively accumulated over time in iNKT cell cultures, being
detectable as soon as 36 h, Il9mRNAwas already detectable after
12 h of culture, peaked at 36 h, and continuously decreased
thereafter (Fig. 4A, 4B, left panels). Kinetics of Il9 expression in
CD4 T cells cultured in presence of TGF-b and IL-4 were distinct,
with ∼24 h of delay at both mRNA and protein levels when com-
pared with iNKT cells. Hence, IL-9 in CD4 T cell culture super-
natants was detectable only after 60 h of stimulation, and Il9
mRNA could be detected at 36 h, reaching the highest expression
between 60 and 84 h of culture (Fig. 4A, 4B, right panels). Of note,
both iNKT and CD4 T cells did not express Il9 mRNA at the be-
ginning of cultures.
iNKT cells isolated from different organs, namely thymus,
spleen, and liver, upregulated Il9 mRNA expression and secreted
IL-9 to the culture supernatant in response to TGF-bwith different
kinetics (Supplemental Fig. 1).
We then assessed the expression of transcription factors relevant
for Th9 differentiation at the peak of the Il9 mRNA response, which
corresponds to 36 and 60 h, respectively, for iNKT and CD4 T cells
(Fig. 4C). After calculating their relative expression (using Eif1a
as internal reference), the fold expression of Sfpi1 (the gene coding
for PU.1), Batf, Irf4, and Gata3 was normalized to their corre-
sponding expression ex vivo, that is, at the culture onset. Notably,
with exception ofGata3, which was downregulated in iNKT cells,
the expression profile of the different genes was qualitatively
similar between iNKT and CD4 T cells, suggesting that Il9 ex-
pression is regulated by the same factors in the two lymphocyte
populations (Fig. 4C). Because Irf4 was the gene showing the
highest level of upregulation at the peak of Il9 response, we studied
mice with a deletion of the Irf4 gene in the hematopoietic com-
partment to address the importance of IRF-4 for the induction of Il9
gene expression in iNKT cells. These mice were generated by
crossing Vav-iCre with Irf4fl/fl mice, in which Irf4 deletion could
be tracked through expression of enhanced GFP. Purified splenic
FIGURE4. Kinetics of IL-9 expression in iNKT cells and transcription factors associatedwith its induction. Splenic iNKTandCD252CD4T cells from
C57BL/6 mice were purified by FACS and stimulated in the presence of IL-2 and, respectively, TGF-b or TGF-b plus IL-4. IL-9 concentration in
supernatants was measured every 24 h and cells were harvested for RNA extraction and gene expression analysis using quantitative RT-PCR. (A) Ac-
cumulation of IL-9 protein in the supernatant of iNKT (left) and CD4 (right) cell cultures over time. Numbers in the horizontal axes indicate hours after
culture set up. (B) Relative amount of Il9 transcripts in iNKT cells (left) and CD4 T cells (right) at the indicated time points. Gene expression is relative to
Eif1a expression level. (C) Fold expression difference of the indicated transcription factors in iNKT and CD4 T cells at the peak of Il9 expression in
relationship to ex vivo. Gene expression was normalized to ex vivo expression levels and is relative to Eif1a. (D and F) Concentration of IL-9 in culture
supernatants of iNKT (left) andCD4T cells (right) isolated from IRF-4+/+ and IRF-42/2 (D) or BATF+/+ andBATF2/2 (F)mice. Supernatants of iNKTand
CD4 T cell cultures were analyzed, respectively, at 60 and 84 h. (E andG) Relative expression of Il9mRNA in iNKT (left) and CD4 T cells (right) isolated
from IRF-4+/+ and IRF-42/2 (E) or BATF+/+ and BATF2/2 (G) mice and analyzed, respectively, after 60 or 84 h of culture. Gene expression is relative to
Eif1a expression level. (H) IL-4 concentration assessed after 60 h of culture in the supernatant of IRF4+/+ and IRF-42/2 (left) and BATF+/+ and BATF2/2
(right) iNKT cell cultures. (I) IL-9 concentration assessed after 60 h of culture in supernatants of IRF4+/2 and IRF-42/2 (left) and BATF+/+ and BATF2/2
(right) iNKT cell cultures supplemented with 10 mg/ml IL-4. Bar graphs represent the average of triplicate or quadruplicate cell cultures per assay, and
error bars indicate SE. Data are representative of two (C–I) or three (A and B) independent experiments. *p , 0.05.















iNKT and CD4 T cells from IRF-4–suficent and –deficient mice
were cultured under Th9-polarizing conditions, as described
above. Supernatants were harvested 1 d after the peak of Il9mRNA
response. Both Irf42/2 iNKT and CD4 T cells had significantly
lower IL-9 secretion (Fig. 4D). These results were also mirrored at
mRNA level, with Irf42/2 cells showing fewer Il9 transcripts
(Fig. 4E).
Because Batf was also upregulated in iNKT cells after IL-9
induction, we assessed IL-9 expression at protein and mRNA
levels in Batf2/2 iNKT and CD4 T cells. Similarly to what was
observed with Irf4 deficiency, Batf2/2 cells showed a marked
decrease in IL-9 secretion and Il9mRNAexpression (Fig. 4F, 4G).
To exclude that Irf42/2 and Batf2/2 mice have basal defects
on iNKT cell development that could bias the aforementioned
results, we analyzed iNKT cells in Irf42/2 and Batf2/2 naivemice
(Supplemental Fig. 2). The frequency and number of iNKT cells in
the spleen and liver were not significantly different in either Irf42/2
and Batf2/2mice in comparison with wild-type mice (Supplemental
Fig. 2A, 2C). Furthermore, the composition of iNKT cell subsets,
defined by CD4 and NK1.1 expression, was also similar in the two
mouse strains (Supplemental Fig. 2B, 2D).
BecausebothIRF-4andBATFarealso implicated in theregulation
of IL-4 expression (35, 36), the impact of Irf4 andBatf deficiency on
IL-9 induction could be due to an impairment of endogenous IL-4
secretion in iNKT cells. Indeed, Irf42/2 andBatf2/2 iNKT cells had
decreased IL-4 production (Fig. 4H). However, supplementation of
culture media with exogenous IL-4 was not sufficient to rescue full
secretion of IL-9, indicating that Irf4 and Batf deficiency directly
affect the capacity of iNKT cells to express IL-9 (Fig. 4I).
These data indicate that the genetic network controlling Il9 ex-
pression is probably similar between iNKT and CD4 T cells.
IL-9+ iNKT cells can contribute to the development of allergic
inflammation
It was previously reported IL-9–producing iNKT cells can confer
protection against DSS-induced colitis (25). Because iNKT cells
showed an outstanding capacity of secreting elevated amounts of
IL-9, and conventional Th9 CD4 T cells are known to contribute to
allergic inflammation by promoting proliferation of mast cells and
goblet cells, as well as influx and local maturation of eosinophils
(37–39), we investigated whether iNKT cells could contribute to
allergic airway inflammation. Classical mouse models of allergic
airways diseasewere not suitable for this aim because 1) they do not
allow a reliable correlation between NKT9 with any disease pa-
rameter because IL-9 expression by iNKT cells occurs early after
activation and is only transient, as shown in Fig. 4, requiring
iNKT cells to be analyzed several days before the initial disease
manifestations; and 2) other innate cells, such as innate lymphoid
cells, also produce IL-9 (40), thus making it hard to discriminate the
specific contribution of iNKT cells for the early IL-9 response. To
circumvent these obstacles, we induced IL-9 expression in splenic
iNKT cells isolated from Foxp3gfp reporter mice in vitro, as de-
scribed above, and after 48 h of culturewe sorted Foxp3+ andFoxp3–
iNKT cells, considering that the latter would be enriched in NKT9
cells (according to data in Fig. 2). Wild-type C57BL/6J mice re-
ceived by intratracheal (i.t.) injection 5 3 104 cells Foxp3+ or
Foxp32 iNKT cells and, without any further immunization, mice
were sacrificed 48 h after cell transfer. This strategy allowed us to
control the time of IL-9 induction in iNKT cells and ensured that the
main secretion of IL-9would come from iNKT cells. Analysis of the
cellular content of the BAL revealed significant infiltration of
eosinophils (defined as MHC class II2Gr-1int) and mast cells (de-
fined as MHC class II2Gr-12c-Kit+) in the airways of recipients
of NKT9 cells (Fig. 5A, 5B).
In a second approach, Foxp3– iNKT cells were generated in
cultures with TGF-b (IL-9+ iNKT) or under conditions adverse to
Th9 polarization (without TGF-b and in presence of 11B11; ac-
tivated iNKT). Cells (1 3 104) of each iNKT population were
transferred i.t. to wild-type recipients subsequently challenged
intranasally with HDM and TSLP) for 5 d before analysis of air-
ways inflammation. Recipients of NKT9 cells had increased in-
flammatory infiltrates in the BAL, particularly eosinophils and
mast cells (Fig. 5C, 5D), and histological analysis of the lungs
revealed higher prevalence of peribronchiolar inflammatory
infiltrates (Fig. 5E). Importantly, neutralization of IL-9 prevented
the accumulation of eosinophils and mast cells in the airways
(Fig. 5F, 5G). This observation shows that the inflammatory in-
filtrates observed following adoptive transfer of IL-9–secreting
iNKT cells are due to IL-9 production (Fig. 5F, 5G).
Taken together, our results show that IL-9–secreting iNKT cells
can contribute to allergic airways disease.
Discussion
Functional diversification in the thymus allows NKT cells in the
periphery to rapidly execute their distinct functional imprinted
programs upon TCR stimulation, namely, IFN-g, IL-4, or IL-17
secretion. Hence, it is possible to identify NKT cells expressing
basal levels of mRNA molecules coding for IFN-g, IL-4, or IL-17
in non–immunized mice, and to detect intracytoplasmic expres-
sion of the correspondent proteins after stimulation with PMA and
ionomycin (Fig. 1, Ref. 41). The ability of peripheral NKT cells
to specialize in distinct functional subsets has been controversial
(11, 35–38). However, Foxp3 expression and acquisition of B cell
helper capacity are not found in naive mice, but arise upon im-
munization (16–19). These observations strongly support the view
thatNKTcells are capable ofmodulating their function in response
to signals received in the periphery, which is corroborated by the
fact that iNKT cells escaping retinoic acid–related orphan receptor
gt imprinting in the thymus can later adopt an NKT17 phenotype
and produce IL-17 when activated under Th17 proinflammatory
conditions (28, 29).
We report in the present study that, despite being undetectable
in non–immunized mice, IL-9 expression by iNKT cells can be
readily induced upon stimulation under appropriate inflammatory
conditions, namely, in the presence of TGF-b and IL-4. These are
also the key cytokines promoting Th9 differentiation of conven-
tional CD4T cells (30, 31). The regulation of Th9 differentiation is
not yet fully understood, but it is thought to rely on the balance
of several transcription factors, including PU.1, BATF, IRF-4,
and GATA-3 (35, 42). Except for Gata3 mRNA, which also reg-
ulates development, survival, activation, and effector function of
iNKT cells (25), the gene regulatory network more specific for the
Th9 program, namely PU.1, BATF, and IRF-4, displayed a similar
kinetic profile between iNKTand CD4T cells, strongly suggesting
that IL-9 expression is regulated through similar mechanisms in
both cell types. Irf4 and Batf were the only genes exhibiting a
heightened expression in iNKT cells, in comparison with ex vivo.
Accordingly, IRF-4 and BATF deficiency have a significant impact
on IL-9 production by iNKT cells, although redundant mecha-
nisms are likely to operate because abrogation of IL-9 production
is incomplete in both cases.
Whereas CD4 T cells require several days to undergo full Th9
differentiation and initiate IL-9 secretion (Fig. 4, Refs. 30, 31), we
show that IL-9 production by iNKT cells occurs in a brief burst
shortly after activation, within the first 36 h, exhibiting an explo-
sive profile in terms of magnitude of secretion and rapid termina-
tion. BecausemRNA coding for IL-9 is undetectable in iNKT cells
isolated ex vivo, themechanisms operating in iNKT cells to induce















FIGURE 5. IL-9–secreting iNKT cells promote
allergic airway inflammation. Splenic iNKT cells
isolated from Foxp3gfp reporter micewere purified
by FACS and stimulated in vitro for 48 h in the
presence of IL-2 and 11B11 or IL-2 and TGF-b.
Cells were then sorted according to GFP expres-
sion and adoptively transferred into wild-type
C57BL/6J mice. (A and B) Mice received by i.t.
injection 5 3 104 Foxp32 (enriched for NKT9,
IL-9+ iNKT cells) or Foxp3+ iNKT cells generated
in cultures supplemented with TGF-b and were
sacrificed 48 h following cell transfer. FACS plots
show the cell content of the BAL, and bar graphs
represent absolute cell numbers of eosinophils and
mast cells defined, respectively, as MHC class II2
Gr-1int andMHCclass II2Gr-12c-Kit+ cells. (C–E)
Wild-type mice received by i.t. injection 1 3 104
Foxp32 iNKT cells from cultures set in the pres-
ence of IL-2 plus 11B11 (activated iNKT) or IL-2
plus TGF-b (enriched for NKT9, IL-9+ iNKT) and
were challengeddailywithHDMandTSLPfor5d.
(C) Cell composition of the BAL assessed by flow
cytometry. (D) Absolute cell counts of eosinophils
and mast cells, as defined above. (E) Airway his-
tology from the different experimental groups
showing staining with H&E. Scale bars, 200 mm.
(F and G) Wild-type mice adoptively transferred
and immunized as described in (C)–(E) were in-
jected with anti–IL-9 (9C1). (F) Cell composition
of the BAL assessed by flow cytometry. (G) Ab-
solute cell counts of eosinophils and mast cells, as
defined above.















IL-9 expression are remarkably fast. This places NKT9 cells in the
first line of Th9 responses, which are typically elicited in mucosal
sites where NKT lymphocytes are abundant, as early contributors
of the initial burst of IL-9 production, as was previously shown in
the case of gut protection from induced colitis (25). Additionally,
human iNKT cells conserve the same ability to respond to TGF-b
and IL-4 by inducing IL-9 expression. The relative contribution of
NKT9 and Th9 cells over time for IL-9–mediated immunity
deserves further investigation.
We observed that addition of exogenous TGF-b alone was suf-
ficient to trigger IL-9 production by iNKT cells, because IL-4 was
provided by iNKT cells endogenously. Nevertheless, both TGF-b
and IL-4 were required to drive optimal IL-9 secretion, as neu-
tralization of either IL-4 or TGF-b would severely impair NKT9
induction. In the absence of TGF-b, low levels of IL-9 could still be
detected. However, addition of a TGF-b–neutralizing Ab com-
pletely abrogated IL-9 production, suggesting the presence of re-
sidual traces of TGF-b in cultures provided either by the serum
used to supplement culturemedia, or byNKT cells themselves (43,
44). In turn, neutralization of IL-4 did not completely abrogate
IL-9 production, suggesting that IL-4 could be acting in an auto-
crine and immediate way on iNKT cells, thus preventing the Ab to
have a complete blocking action.
Thefact that iNKTcellsubpopulationsdefinedbyNK1.1andCD4,
orNrp-1expression,whichhavedifferential tissuedistributions (26),
are fully competent to induce IL-9 expression suggests that NKT9
cells can be generated in several tissues when appropriate inflam-
matory signals are present. The highest IL-9 secretion was observed
among subsets expressing NK1.1, which can secrete IL-4, but are
especially enriched in IFN-g–producing iNKT cells (45, 46). This
observation is interesting in the light of recent findings showing the
importance of IL-9 for antitumor responses, by promoting appro-
priate homing of cytotoxic lymphocytes to tumor sites and enabling
them to efficiently seek out and destroy target cancer cells (47, 48).
The ability of iNKT cells to boost antitumor immune responses is
well known and attributed to their rapid IFN-g secretion (49). The
finding that NKT9 potential is maximal among the NK1.1+ iNKT
compartment, which is the one providing the most efficacious re-
sponse to cancer, suggests that, in addition to IFN-g, iNKT cell–
derived IL-9might also contribute to reinforce antitumor responses.
Of note, TGF-b is commonly produced in tumor sites (50).
In addition to cancer, IL-9–dependent responses have also been
associated with autoimmune and allergic diseases, which are im-
mune responses where iNKT cell intervention has been exten-
sively documented (42, 47, 48, 51, 52). Because the contribution of
IL-9 for the development of allergic airways inflammation is well
established (33, 34, 53), we investigated the impact of IL-9 pro-
duced by iNKT cells in that condition. Our results show that the
presence of IL-9–secreting iNKT cells in the airways, even at low
numbers, increases local infiltration by eosinophils and mast cells.
Despite that iNKT cells have been reported to respond directly to
TSLP by increasing IL-13 production and lead to increased eo-
sinophilia in a mouse model of OVA-induced allergic airways
disease (54), in vivo blockade of IL-9 completely prevented local
accumulation of eosinophils and, to a great extent, mast cells. This
outcome demonstrates that IL-9 is the main factor driving airway
infiltration in this model. Taken together, these data indicate that
NKT9 cells can contribute to accelerate the onset of and boost Th9
responses at mucosal sites.
In conclusion, following completion of thymic development,
NKT cells remain receptive to functional polarization in the pe-
riphery. Activation in presence of TGF-b and IL-4 leads to NKT9
polarization and IL-9 production. However, IL-9 production does
not appear restricted to a particular iNKT subset, corresponding
rather to a functional state. In comparison with conventional Th9
cells, secretion of IL-9 by iNKT cells is faster, shorter, and higher
in magnitude, favoring an innate role for NKT9 cells at the early
phase of Th9 responses. Accordingly, adoptive transfer of NKT9
cells exacerbated allergic airways inflammation, thus demon-
strating the impact of this functional subset in vivo.
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Supplementary Figure 1: Kinetics of Il9 mRNA expression and IL-9 
secretion by iNKT cells isolated from thymus, spleen and liver 
 
Splenic iNKT cells isolated from thymus, spleen and liver of Balb/c WT mice 
were stimulated in presence of IL-2 the indicated antibodies or cytokines. IL-9 
concentration in supernatants was measured every 24 hours and cells were 
harvested for RNA extraction and gene expression analysis using qRT-PCR. 
(A) Relative amount of Il9 transcripts in iNKT cells cells at the indicated time 
points. Gene expression is relative to Eif1a expression level. Il9 expression 
was undetectable ex vivo in iNKT cells isolated from all the organs (not 
depicted). 
(B) Concentration of IL-9 protein in the supernatant of iNKT-cell culture 
supernatant 60 hours after set up. 
N.D. = not detected. Bar graphs represent the average of triplicate cell culture 
wells per assay, except for mRNA expression in the liver, in which one well 




Supplementary Figure 2: Analysis of iNKT cells at the steady state in 
Batf–/– and Irf4–/– mice. 
 
iNKT cells were isolated from spleen and liver of Batf–/– (A,B) or Irf4–/– (C,D) 
unmanipulated mice, and analyzed by flow cytometry in comparison with WT 
age-matched controls. 
	  
(A) Flow cytometry identification of iNKT cells in the spleen and liver of WT 
and Batf–/– mice. Dotplots were gated in the CD19– population. Quantification 
of iNKT-cell absolute numbers is provided on the right. 
(B) Flow cytometry profile (left) and frequency of iNKT-cell subsets defined by 
CD4 and NK1.1 expression (right) in WT and Batf–/– mice. Dotplots were 
gated in TCRβintCD1d/PBS57+ cells. 
(C) Flow cytometry identification of iNKT cells in the spleen and liver of WT 
and Irf4–/– mice. Dotplots were gated in the CD19– population. Quantification 
of iNKT-cell absolute numbers is provided on the right. 
(D) Flow cytometry profile (left) and frequency of iNKT-cell subsets defined by 
CD4 and NK1.1 expression (right) in WT and Irf4–/– mice. Dotplots were gated 
in TCRβintCD1d/PBS57+ cells. 
 
n.s. = not significant. Results are representative of two independent 
experiments with three to five animals per group. Bar graphs represent the 
average and error bars indicate standard error. 
 
